KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) Inventory Average (2016 - 2025)

Historic Inventory Average for West Pharmaceutical Services (WST) over the last 17 years, with Q4 2025 value amounting to $441.0 million.

  • West Pharmaceutical Services' Inventory Average rose 1332.56% to $441.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $441.0 million, marking a year-over-year increase of 1332.56%. This contributed to the annual value of $410.4 million for FY2025, which is 113.34% up from last year.
  • As of Q4 2025, West Pharmaceutical Services' Inventory Average stood at $441.0 million, which was up 1332.56% from $429.6 million recorded in Q3 2025.
  • Over the past 5 years, West Pharmaceutical Services' Inventory Average peaked at $448.2 million during Q2 2023, and registered a low of $315.8 million during Q1 2021.
  • Moreover, its 5-year median value for Inventory Average was $413.2 million (2022), whereas its average is $403.2 million.
  • Per our database at Business Quant, West Pharmaceutical Services' Inventory Average skyrocketed by 2975.14% in 2021 and then crashed by 1143.88% in 2025.
  • Over the past 5 years, West Pharmaceutical Services' Inventory Average (Quarter) stood at $366.1 million in 2021, then increased by 13.07% to $414.0 million in 2022, then increased by 4.66% to $433.2 million in 2023, then dropped by 10.19% to $389.1 million in 2024, then grew by 13.33% to $441.0 million in 2025.
  • Its last three reported values are $441.0 million in Q4 2025, $429.6 million for Q3 2025, and $404.9 million during Q2 2025.